EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches

Toby A Eyre iD, Chan Y Cheah iD, Clémentine Sarkozy iD, Anita Kumar iD, Steven Le Gouill iD

Journal of Clinical Oncology · 10.07.2025 · 43 (20) · 2300-2310

DOI: 10.1200/jco-25-00146 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.07.2025. Verfasst von Toby A Eyre und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Churchill Drive, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent Bruton tyrosine kinase (cBTK) inhibition has been demonstrated to be highly effective with cBTK inhibitor monotherapy, an established standard of care in relapsed MCL. This review summarizes the recent data strongly suggesting a role for the integration of covalent BTK inhibition in the first-line treatment setting, after the recent presentation and publication of multiple phase II and randomized phase II/III clinical trials demonstrating benefit for the addition of cBTK inhibitors first line. The authors discuss herein the strength and quality of the evidence for therapeutic strategies integrating cBTK inhibitors first line and proposal treatment algorithms on the basis of assumed future availability of this highly active small molecules first line in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsHumansMolecular Targeted TherapyRandomized Controlled Trials as Topic

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsBTK protein, human

Autor:innen und Institutionen

  • Oxford Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Churchill Drive, Oxford, United Kingdom.
  • Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia.
  • Service d'hématologie, Institut Curie, Saint Cloud, France.
  • Université de Versailles Saint-Quentin, Versailles, France.
  • Laboratoire d'Imagerie Translationnelle en Oncologie, U1288 INSERM/Institut Curie Centre de Recherche, Paris, France.
  • Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Toby A Eyre, Chan Y Cheah, Clémentine Sarkozy, Anita Kumar, Steven Le Gouill

Zitieren

APA

Eyre, T. A., Cheah, C. Y., Sarkozy, C., Kumar, A., & Le Gouill, S. (2025). Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches. Journal of Clinical Oncology, 43(20), 2300-2310. https://doi.org/10.1200/jco-25-00146

Vancouver

Eyre TA, Cheah CY, Sarkozy C, Kumar A, Le Gouill S. Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches. Journal of Clinical Oncology. 2025;43(20):2300-2310. doi:10.1200/jco-25-00146

BibTeX
@article{Eyre2025,
  author = {Eyre, Toby A and Cheah, Chan Y and Sarkozy, Clémentine and Kumar, Anita and Le Gouill, Steven},
  title = {Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {20},
  pages = {2300--2310},
  doi = {10.1200/jco-25-00146}
}
Kostenlos starten →